Page 537 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 5

121. Bergqvist D. The role of vena caval interruption in patients with massive pulmonary embolism: a European multicenter double-
venous thromboembolism. Prog Cardiovasc Dis. July-August blind trial. The European Cooperative Study Group for Pulmonary
1994;37(1):25-37. Embolism. J Am Coll Cardiol. February 1992;19(2):239-245.
122. Clagett GP, Anderson FA Jr, Geerts W, et al. Prevention of venous 138. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B,
thromboembolism. Chest. November 1998;114(suppl 5):531S-560S. Simonneau G. Hemodynamic effects of bolus vs 2-h infusion
123. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase of alteplase in acute massive pulmonary embolism. A random-
combined with heparin versus heparin in the treatment of ized controlled multicenter trial. Chest. September 1994;106(3):
acute pulmonary embolism. Plasminogen activator Italian 712-717.
multicenter study 2. J Am Coll Cardiol. September 1992;20(3): 139. Goldhaber SZ, Feldstein ML, Sors H. Two trials of reduced
520-526. bolus alteplase in the treatment of pulmonary embolism. An
124. Witty LA, Krichman A, Tapson VF. Thrombolytic therapy for overview. Chest. September 1994;106(3):725-726.
venous thromboembolism. Utilization by practicing pulmon- 140. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus
ologists. Arch Intern Med. July 25, 1994;154(14):1601-1604. alteplase vs conventional alteplase infusion for pulmonary
125. Diehl JL, Meyer G, Igual J, et al. Effectiveness and safety of bolus embolism thrombolysis. An international multicenter random-
administration of alteplase in massive pulmonary embolism. ized trial. The Bolus Alteplase Pulmonary Embolism Group.
Am J Cardiol. December 1, 1992;70(18):1477-1480. Chest. September 1994;106(3):718-724.
126. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus 141. Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and
heparin in acute pulmonary embolism: randomised trial assess- intrapulmonary recombinant tissue-type plasminogen activa-
ing right-ventricular function and pulmonary perfusion. Lancet. tor in the treatment of acute massive pulmonary embolism.
February 27, 1993;341(8844):507-511. Circulation. February 1988;77(2):353-360.
127. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, 142. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-
et al. Streptokinase and heparin versus heparin alone in massive type plasminogen activator versus a novel dosing regimen of uro-
pulmonary embolism: a randomized controlled trial. J Thromb kinase in acute pulmonary embolism: a randomized controlled
Thrombolysis. 1995;2(3):227-229. multicenter trial. J Am Coll Cardiol. July 1992;20(1):24-30.
128. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl 143. Stein PD, Hull RD, Raskob G. Risks for major bleeding from
J Med. October 10, 2002;347(15):1131-1132. thrombolytic therapy in patients with acute pulmonary embo-
lism. Consideration of noninvasive management. Ann Intern
129. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary Med. September 1, 1994;121(5):313-317.
embolism: a comprehensive review of current evidence. Chest.
June 1999;115(6):1695-1707. 144. Molina JE, Hunter DW, Yedlicka JW, Cerra FB. Thrombolytic
therapy for postoperative pulmonary embolism. Am J Surg.
130. Hamel E, Pacouret G, Vincentelli D, et al. Thrombolysis or April 1992;163(4):375-380; discussion 371-380.
heparin therapy in massive pulmonary embolism with right
ventricular dilation: results from a 128-patient monocenter 145. Girard P, Baldeyrou P, Le Guillou JL, Lamer C, Grunenwald
registry. Chest. July 2001;120(1):120-125. D. Thrombolysis for life-threatening pulmonary embolism
131. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. 2 days after lung resection. Am Rev Respir Dis. June 1993;147(6
pt 1):1595-1597.
Heparin plus alteplase compared with heparin alone in patients
with submassive pulmonary embolism. N Engl J Med. October 146. Severi P, Lo Pinto G, Poggio R, Andrioli G. Urokinase thrombo-
10, 2002;347(15):1143-1150. lytic therapy of pulmonary embolism in neurosurgically treated
patients. Surg Neurol. December 1994;42(6):469-470.
132. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embo-
lism: clinical outcomes in the International Cooperative 147. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg
Pulmonary Embolism Registry (ICOPER). Lancet. April 24, CS. Bleeding during thrombolytic therapy for acute myocardial
1999;353(9162):1386-1389. infarction: mechanisms and management. Ann Intern Med.
December 15, 1989;111(12):1010-1022.
133. Kreit JW. The impact of right ventricular dysfunction on the
prognosis and therapy of normotensive patients with pulmo- 148. Belenkie I, Dani R, Smith ER, Tyberg JV. Effects of volume
nary embolism. Chest. April 2004;125(4):1539-1545. loading during experimental acute pulmonary embolism.
Circulation. July 1989;80(1):178-188.
134. Meyer G, Vicaut E, Thierry D. Fibrinolysis for Patients with
Intermediate Risk Pulmonary Embolism. NEJM. 2014;370(15): 149. Jardin F, Genevray B, Brun-Ney D, Margairaz A. Dobutamine:
1402-1411. a hemodynamic evaluation in pulmonary embolism shock. Crit
135. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of Care Med. December 1985;13(12):1009-1012.
a two-hour regimen of streptokinase versus alteplase in acute 150. Molloy WD, Lee KY, Girling L, Schick U, Prewitt RM. Treatment
massive pulmonary embolism: immediate clinical and hemo- of shock in a canine model of pulmonary embolism. Am Rev
dynamic outcome and one-year follow-up. J Am Coll Cardiol. Respir Dis. November 1984;130(5):870-874.
April 1998;31(5):1057-1063. 151. Boulain T, Lanotte R, Legras A, Perrotin D. Efficacy of epi-
136. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs nephrine therapy in shock complicating pulmonary embolism.
alteplase in massive pulmonary embolism. A randomized trial Chest. July 1993;104(1):300-302.
assessing right heart haemodynamics and pulmonary vascular 152. Estagnasie P, Le Bourdelles G, Mier L, Coste F, Dreyfuss D. Use
obstruction. Eur Heart J. July 1997;18(7):1141-1148. of inhaled nitric oxide to reverse flow through a patent foramen
137. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous ovale during pulmonary embolism. Ann Intern Med. May 1,
urokinase versus alteplase on total pulmonary resistance in acute 1994;120(9):757-759.

Section03-O-ref.indd 5 1/20/2015 7:10:28 AM